Cross-cultural adaptation of the Myocardial Infarction Dimensional Assessment Scale (MIDAS) to the Brazilian Portuguese language

Resumo A partir da avalia ção dos fatores que incidem na qualidade de vida (QV) é possível planejar as intervenções que proporcionam melhoria do bem-estar dos pacientes. Realizar a adaptação transcultural do questionário Miocardial Infarction Dimensional Assessment Scale (MIDAS) para língua portuguesa, buscando as equivalências semântica, idiomática, conceitual e cultural. Foi utilizado o referencial teórico de Guillemin, Bombardier e Beaton, cumprindo as seguintes etapas: tradução, retrotradução, avaliação dos autores, banca de juízes e pré-teste. Após todas as avaliações, foram alcançadas as equivalências semântica, conceitual, idiomática e cultural. A escala mostrou-se de fácil aplicação e importância clínica. O MIDAS encontra-se validado no que se refere às equivalências semânticas, idiomáticas, conceituais e culturais. Posteriormente, será avaliada a equivalência de me nsuração, para verificar as propriedades psicométricas.Abstract From the evaluation of the factors that affect quality of life (QOL) it is possible to plan interventions that lead to the improved well-being of patients. The scope of this study was to conduct the cross-cultural adaptation of the Myocardial Infarction Di...
Source: Ciencia e Saude Coletiva - Category: Occupational Health Source Type: research

Related Links:

DNA tests might identify ‘invisible population’ who are not currently seen as in dangerHundreds of thousands more adults in the UK could benefit from taking statins because their genes put them at high risk of heart disease, research suggests.Speaking on Wednesday at the UK Biobank conference in London, Prof Sir Peter Donnelly, the founder of the company Genomics Plc, warned of an “invisible population” who are not identified as at risk by current screening programmes because their blood pressure and cholesterol do not raise red flags.Continue reading...
Source: Guardian Unlimited Science - Category: Science Authors: Tags: Medical research Heart disease Health Heart attack Science Society UK news Source Type: news
Condition:   ST Elevation Myocardial Infarction Interventions:   Drug: ATH3G10;   Drug: Placebo Sponsor:   Athera Biotechnologies AB Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Predictors for post-sepsis myocardial infarction (MI) and stroke are yet to be identified due to the competing risk of death. Baseline comorbidities and sources of infection were associated with an increased risk of post-sepsis MI and stroke. The identified risk factors may help physicians select a group of patients with sepsis who may benefit from preventive measures, antiplatelet treatment, and other preventive measures for post-sepsis MI and stroke.
Source: Current Awareness Service for Health (CASH) - Category: Consumer Health News Source Type: news
We report a 30-year-old woman with relapsing-remitting multiple sclerosis who developed a type 2 non-ST elevated myocardial infarction (NSTEMI) during her first alemtuzumab infusion cycle. While acute coronary syndrome has been described with alemtuzumab in the treatment of lymphoma, alemtuzumab-associated cardiac ischemia in multiple sclerosis is uncommon and can occur in patients without cardiovascular risk factors.
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research
Jon Lorsch, from Swarthmore College’s class of 1990, returned to his alma mater in May to accept an honorary Doctor of Sciences degree for his accomplishments as a biochemist and his visionary leadership of NIGMS. During the university’s 147th commencement, he spoke to the 2019 graduating class, offering advice and examples of how we can look for opportunities in the least likely places. Watch the 5-minute video to hear Lorsch’s advice to the graduates—and all future scientists—to venture into the unknown in search of the next big advance in biomedical research. Transcript of Lors...
Source: Biomedical Beat Blog - National Institute of General Medical Sciences - Category: Research Authors: Tags: Being a Scientist Scientific Process Source Type: blogs
An in-depth look at violence and its relation to schizophrenia. Is violence a symptom of schizophrenia? Do mass attackers always have schizophrenia? Are schizophrenics dangerous? Studies say people with schizophrenia are more likely to be a victim of a crime than the perpetrator. However, James Holmes, the movie theater mass murderer, was said to have paranoid schizophrenia. And a person can plead not-guilty by reason of insanity in court. This seems to be contrary to the idea of non-violence in mental illness. Host Rachel Star Withers, a diagnosed schizophrenic, and co-host Gabe Howard delve into these intense subjects i...
Source: World of Psychology - Category: Psychiatry & Psychology Authors: Tags: Inside Schizophrenia Stigma Violence and Aggression Mental Disorder Mental Health Mental Illness Paranoid Schizophrenia violence and mental illness violence and mentally ill Source Type: blogs
Philip Morris - the nation's largest cigarette manufacturer - is about to land a huge legislative gift from the most unlikely of sources: the San Francisco Board of Supervisors.Earlier today, the Board approved an ordinance that will ban the sale of all electronic cigarettes in the city, including both brick-and-mortar and online sales. Before it becomes law, the ordinance is subject to a final vote, which is expected to take place next week.The Philip Morris USA cigarette company could not have dreamed for a more favorable legislative gift from the city of San Francisco. Right now, the chief competitor to the sale of the ...
Source: The Rest of the Story: Tobacco News Analysis and Commentary - Category: Addiction Source Type: blogs
The U.S. Food and Drug Administration (FDA) is updating the public about its ongoing safety review of abacavir and a possible increased risk of heart attack.
Source: FDA Center for Drug Evaluation and Research - What's New - Category: Drugs & Pharmacology Authors: Source Type: news
[2-03-2011] The U.S. Food and Drug Administration (FDA) is notifying the public that information on the cardiovascular risks (including heart attack) of the diabetes drug rosiglitazone has been added to the physician labeling and patient Medication Guide.
Source: FDA Center for Drug Evaluation and Research - What's New - Category: Drugs & Pharmacology Authors: Source Type: news
Publication date: Available online 31 May 2019Source: Journal of the Saudi Heart AssociationAuthor(s): Leia Hee, Oliver J. Gibbs, Joseph G. Assad, Lokesh D. Sharma, Andrew Hopkins, Craig P. Juergens, Sidney Lo, Christian J. MussapAbstractObjectivesThe primary aim was to investigate the efficacy and safety of dual antiplatelet therapy (DAPT) using ticagrelor (T-DAPT) versus clopidogrel (C-DAPT) in a real-world ST-elevation myocardial infarction (STEMI) population.MethodsWe retrospectively analyzed 655 consecutive patients having primary percutaneous coronary intervention (PCI) for STEMI at Liverpool Hospital, Sydney, Austra...
Source: Journal of the Saudi Heart Association - Category: Cardiology Source Type: research
More News: Brazil Health | Heart Attack | Portugal Health | Study